SteelPeak Wealth LLC Acquires 21,227 Shares of Teladoc Health, Inc. (NYSE:TDOC)

SteelPeak Wealth LLC increased its stake in Teladoc Health, Inc. (NYSE:TDOC) by 151.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,254 shares of the health services provider’s stock after buying an additional 21,227 shares during the period. SteelPeak Wealth LLC’s holdings in Teladoc Health were worth $345,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TDOC. Hexagon Capital Partners LLC grew its position in shares of Teladoc Health by 204.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after buying an additional 1,065 shares in the last quarter. Allianz Asset Management GmbH increased its position in Teladoc Health by 15.4% during the 4th quarter. Allianz Asset Management GmbH now owns 604,238 shares of the health services provider’s stock valued at $13,021,000 after purchasing an additional 80,805 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Teladoc Health by 74.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 20,568 shares of the health services provider’s stock valued at $311,000 after purchasing an additional 8,750 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Teladoc Health by 188.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 31,594 shares of the health services provider’s stock worth $477,000 after purchasing an additional 20,651 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Teladoc Health by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.

Insider Buying and Selling

In other Teladoc Health news, Director Thomas Mckinley bought 7,000 shares of Teladoc Health stock in a transaction that occurred on Tuesday, August 6th. The stock was purchased at an average price of $7.57 per share, with a total value of $52,990.00. Following the completion of the acquisition, the director now directly owns 31,077 shares in the company, valued at approximately $235,252.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teladoc Health news, Director Karen L. Daniel sold 9,834 shares of Teladoc Health stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $11.90, for a total value of $117,024.60. Following the completion of the transaction, the director now owns 36,995 shares of the company’s stock, valued at $440,240.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Mckinley acquired 7,000 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was purchased at an average cost of $7.57 per share, with a total value of $52,990.00. Following the acquisition, the director now directly owns 31,077 shares of the company’s stock, valued at approximately $235,252.89. The disclosure for this purchase can be found here. Insiders sold a total of 52,714 shares of company stock valued at $472,714 over the last 90 days. Insiders own 0.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research note on Thursday, August 1st. Royal Bank of Canada cut their target price on Teladoc Health from $25.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research report on Friday, August 2nd. Stifel Nicolaus reduced their price objective on shares of Teladoc Health from $16.00 to $9.00 and set a “hold” rating for the company in a research note on Thursday, August 1st. Finally, Bank of America decreased their target price on shares of Teladoc Health from $16.50 to $13.50 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Fourteen research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $13.56.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded down $0.08 on Friday, hitting $6.98. 275,493 shares of the company were exchanged, compared to its average volume of 5,497,159. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $9.16 and its 200 day moving average price is $12.87. Teladoc Health, Inc. has a 1-year low of $6.77 and a 1-year high of $23.59. The firm has a market capitalization of $1.20 billion, a P/E ratio of -5.01 and a beta of 0.93.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.